Angiotensin

Product Overview

Angiotensin is a prescription medication containing the active pharmaceutical ingredient Lisinopril. As an angiotensin-converting enzyme (ACE) inhibitor, this therapeutic agent is clinically indicated for the management of hypertension (elevated blood pressure), congestive heart failure, and post-myocardial infarction care. The pharmacological action involves vasodilation of blood vessels, resulting in reduced vascular resistance, improved cardiac output, and decreased myocardial workload.

Therapeutic Indications

This pharmaceutical preparation is primarily indicated for:

• Monotherapy or combination therapy for essential hypertension
• Management of chronic heart failure (NYHA Class II-IV)
• Adjuvant therapy post-acute myocardial infarction to improve ventricular function

Dosage and Administration

The recommended posology involves oral administration once daily, with dosage titration based on therapeutic response and tolerability. Key administration guidelines include:

• Standard initial dose for hypertension: 10 mg OD
• Maintenance dose range: 20-40 mg daily
• Heart failure patients: Initiate with 2.5-5 mg OD
• Administer with adequate hydration
• Maintain consistent dosing schedule

Mechanism of Action

The pharmacodynamic profile involves competitive inhibition of angiotensin-converting enzyme (EC 3.4.15.1), preventing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This results in:

• Reduced aldosterone secretion
• Decreased peripheral vascular resistance
• Improved renal blood flow
• Reduced cardiac afterload

Clinical Advantages

• Established efficacy in cardiovascular risk reduction
• Favorable pharmacokinetic profile allowing once-daily dosing
• Demonstrated mortality benefit in post-MI patients
• Renoprotective effects in diabetic nephropathy
• Compatibility with most antihypertensive combination therapies

Adverse Effects

The safety profile includes commonly reported adverse drug reactions:

• Dizziness (10-12% incidence)
• Persistent dry cough (5-8%)
• Headache (4-6%)
• Gastrointestinal disturbances (3-5%)
• Fatigue (2-4%)

Important Safety Information

Contraindications:

• History of angioedema related to ACE inhibition
• Concomitant use with aliskiren in diabetic patients
• Pregnancy (FDA Pregnancy Category D)

Precautions:

• Monitor renal function and serum potassium
• Caution in renal artery stenosis
• Risk of symptomatic hypotension in volume-depleted patients

Storage Conditions

Maintain at controlled room temperature (20-25°C) in original packaging. Protect from moisture and excessive heat. Keep out of reach of pediatric patients.

Medical Disclaimer

The information provided herein represents current pharmacological data but does not constitute medical advice. This monograph is not exhaustive regarding potential drug interactions, contraindications, or adverse effects. Healthcare professionals should reference complete prescribing information. Patients should consult qualified medical practitioners for personalized therapeutic recommendations. This content supports but does not replace professional medical judgment.